Drs. Neil Iyengar, Komal Jhaveri, & Igor Makhlin - HER2+ Metastatic Breast Cancer: Is T-DXd + Pertuzumab the New First-Line Standard?

Community Health Media · Jan 6, 2026 · 35m

For more than a decade, CLEOPATRA defined first-line therapy in HER2-positive metastatic breast cancer.

Now, DESTINY-Breast09 is forcing a fundamental rethink.

In this in-depth roundtable, Drs. Neil Iyengar, Komal Jhaveri, and Igor Makhlin examine:

• The legacy — and limitations — of CLEOPATRA

• DESTINY-Breast09’s unprecedented ~40-month PFS

• When T-DXd + pertuzumab should move to the frontline

• Patient selection, toxicity management, and ILD vigilance

• Sequencing strategies after frontline ADCs

• How maintenance paradigms may evolve

A must-watch discussion on efficacy vs durability…